Neumirna Therapeutics ApS

CVR 41696451 · Private limited company (ApS) · Active · Low risk

Neumirna Therapeutics ApS is a Private limited company (ApS), founded on , based in København SV. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.1% over the next 12 months, which is 0.1 times the average for Danish companies. 5 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 91.8m and a net result of DKK -55.8m.

Bankruptcy risk for Neumirna Therapeutics ApS

0.1%
probability of bankruptcy within 12 months
Low risk

0.1 × the average (1.41%) · higher risk than 38% of active Danish companies

Lowest riskHighest risk

Increases the risk

Return on assets< -20% · bankruptcy rate 16.7%1.9×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
CEOs in total (historical)0 · bankruptcy rate 12.4%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×
Annual reports filed late1 · bankruptcy rate 11.3%1.3×
CEO's other companies0 · bankruptcy rate 10.9%1.2×
Loss for the yearYes · bankruptcy rate 10.3%1.2×

Reduces the risk

Current ratio500%+ · bankruptcy rate 1.5%0.17×
Equity vs. share capital5+× · bankruptcy rate 2.5%0.28×
Time at current address5+ yrs · bankruptcy rate 3.1%0.35×
Equity ratio60%+ · bankruptcy rate 3.3%0.38×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
41696451
Status
Active
Company type
Private limited company (ApS)
Founded
(6 years)
Address
c/o Center for RNA Medicine, AAU CPH, A.C. Meyers Vænge 15
2450 København SV
Municipality
København
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 195k
Auditor
EY Godkendt Revisionspartnerselskab
Audit opted out
No

Warning signs

Annual reports filed late1 of 5
Missing annual reportNo
Negative equityNo
Equity ratio91.5%
Current ratio1,175%
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address2
Going-concern uncertaintyNo

Financials and key figures

Financial year202520242023
Gross profitDKK -53.9mDKK -5.5mDKK -5.5m
Net profitDKK -55.8mDKK -7.0mDKK -8.0m
EquityDKK 91.8mDKK -18.4mDKK -11.5m
Total assetsDKK 100.4mDKK 5.5mDKK 6.3m
CashDKK 88.8mDKK 3.0m–
Short-term debtDKK 8.5mDKK 23.8m–
Avg. employees105–

Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · (venstre underskriver).

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025180
1 Jan 2024 – 31 Dec 2024184 Late
1 Jan 2023 – 31 Dec 2023128
1 Jan 2022 – 31 Dec 2022141
21 Sep 2020 – 31 Dec 2021152

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
BoardHenrik Valdemar KlitgaardCurrent
BoardMilla KoistinahoCurrent
BoardLuis Garcia ParerasCurrent
BoardAndreas WallnöferCurrent
BoardEllen Kinson DonnellyCurrent
BoardFrancesco Paolo Di GiorgioCurrent
BoardMads Spangaard Rasmussen
BoardMarkus Sakari Kauppinen
BoardLars Hellerung Christiansen
BoardMorten Priskorn
BoardLars Hellerung Christiansen
BoardWyle Solomon
BoardMads Spangaard Rasmussen
BoardSten Verland
BoardMads Spangaard Rasmussen
BoardThomas Michael Thestrup
Owner (25%)HELLERUNG ApSCurrent
Owner (15%)Innovestor Life Science Fund KyCurrent
Owner (10%)INVIVO VENTURES III, FCRECurrent
Owner (15%)Angelini Ventures S.p.A.Current
Owner (33%)HELLERUNG ApS
Owner (5%)FONDEN FOR SYDDANSK VÆKSTFREMME
Owner (5%)Krudtmøllen I ApS
Owner (10%)Henrik Valdemar Klitgaard Holding ApS
Owner (15%)Pandion Holding ApS
Owner (5%)Wyle Solomon
Owner (5%)Henrik Valdemar Klitgaard Holding ApS
Owner (5%)Pandion Holding ApS
Owner (5%)INVIVO VENTURES III, FCRE
Owner (10%)Innovestor Life Science Fund Ky
Owner (5%)Angelini Ventures S.p.A.
Owner (10%)Angelini Ventures S.p.A.
AuditorEY Godkendt RevisionspartnerselskabCurrent
AuditorBeierholm Godkendt Revisionspartnerselskab
FounderHELLERUNG ApSCurrent
FounderFONDEN FOR SYDDANSK VÆKSTFREMMECurrent
FounderKrudtmøllen I ApSCurrent
FounderHenrik Valdemar Klitgaard Holding ApSCurrent
FounderPandion Holding ApSCurrent

Address history (1 moves)

c/o Center for RNA Medicine, AAU CPH, A.C. Meyers Vænge 15, 2450 København SV
c/o Beierholm, Knud Højgaards Vej 9, 2860 Søborg

Other companies at the same address

Similar companies in København

Questions and answers about Neumirna Therapeutics ApS

Has Neumirna Therapeutics ApS gone bankrupt?

No, Neumirna Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Neumirna Therapeutics ApS?

Our model estimates a bankruptcy risk of 0.1% over the next 12 months (low risk), which is 0.1 times the average for Danish companies.

Who is the auditor of Neumirna Therapeutics ApS?

Neumirna Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.

When was Neumirna Therapeutics ApS founded?

Neumirna Therapeutics ApS was founded on 21 September 2020.

What is the equity of Neumirna Therapeutics ApS?

Equity was DKK 91.8m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.